Loading...
NPI 1467713685 · Liverpool, NY · Retina Specialist (Ophthalmology) Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Tahsin Choudhury is a retina specialist (ophthalmology) physician provider located in Liverpool, New York. This profile covers 22 Medicare and 3 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Tahsin Choudhury |
| Address | 200 Greenfield Pkwy |
| City | Liverpool |
| State | NY |
| ZIP | 13088 |
| Taxonomy | Retina Specialist (Ophthalmology) Physician |
| NPI Enumerated | June 5, 2012 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.4M |
| Medicaid | $197.9K |
This provider's revenue profile is Medicare-dominant: total Medicare revenue is $3.4M compared with $197.9K in Medicaid, indicating Medicare represents the vast majority of billings and financial scale for clinical operations. Medicaid revenue exists but is an order of magnitude smaller, so payer-driven margin and volume risks will primarily be tied to Medicare reimbursement patterns.
Revenue concentration is extreme on a small set of services for Medicare: the precomputed top 3 Medicare codes account for 84.1% of Medicare revenue, led by J0178 which alone generates $2.3M (68.7% of Medicare revenue). Such concentration signals that administration of aflibercept is the core revenue driver for this practice on Medicare patients.
Medicaid billing is even more concentrated: the precomputed top 3 Medicaid codes account for 100.0% of Medicaid revenue, with J0178 responsible for $166.4K (84.1% of Medicaid revenue) and 67028 and 92134 making up the remainder. This means Medicaid revenue is almost entirely tied to the same injection and retina-imaging services that drive Medicare revenue.
The service mix — dominated by injectable drug codes (J0178, J2777, J2778, J2781) and retina imaging/procedures (92134, 67028) — is consistent with an office-based retina specialty focused on frequent intravitreal injections and high-volume diagnostic imaging. Lower-count surgical codes (for example 67042 and 67108) appear but contribute modestly to total revenue, suggesting the practice primarily operates as an injection-and-clinic-imaging center rather than a surgery-first retina practice.
On competitive standing for Medicare, the provider is a high-volume national participant for key codes: J0178 ranks #121 of 3204 providers nationally (96th percentile) and 92134 ranks #286 of 26868 providers nationally (99th percentile, noted as an "extreme outlier"). These rankings indicate notably above-typical national volume for aflibercept administration and exceptionally high utilization of retinal imaging relative to peers. By contrast, injections such as J2777 and J2778 are at more typical national volumes (mid-percentile rankings).
In-state Medicaid competitiveness is modest: J0178 is ranked #35 of 101 providers in-state (66th percentile), 67028 is #89 of 262 (66th percentile), and 92134 is #225 of 728 (69th percentile), all described as typical or unremarkable volume. That positioning suggests the provider is not a dominant Medicaid player within New York but is a regular, mid-tier participant for these retina services.
Payer-specific payment patterns are visible and operationally relevant: for J0178 the reported average paid/claim is $692 on Medicare versus $293 on Medicaid, showing materially different per-claim reimbursements across payers for the same high-volume drug administration. Given the heavy revenue dependence on injectable drugs, variations in per-claim payments or utilization by payer could materially affect overall revenue.
The provider has an established billing history with NPI enumeration on 2012-06-05 (~14 years ago), which combined with sustained, high-volume billing for injections and retinal imaging implies an operational infrastructure set up for repeat intravitreal treatments and high-throughput diagnostic visits. Continuity in those service lines appears central to the provider's business model and financial performance.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
22 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 3,390 | $690 | $2.3M |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 12,000 | $30 | $348K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2,060 | $90 | $177.4K |
| J2778 | Injection, ranibizumab, 0.1 mg | 700 | $180 | $126.5K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 3,300 | $30 | $95.8K |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | 410 | $120 | $48.6K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 550 | $90 | $47.9K |
| J3490 | Unclassified drugs | 30 | $1,770 | $47.7K |
| J3590 | Unclassified biologics | 20 | $1,840 | $44.2K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 340 | $90 | $30.8K |
Showing 1–10 of 22
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 22 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
22 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 12 | 230 | 560 | $690 | $693K |
| J2777 | 35 | 120 | 7,740 | $30 | $364.9K |
| J2778 | 27 | 70 | 510 | $180 | $131.6K |
| J2781 | 26 | 40 | 520 | $120 | $75.1K |
| J3590 | 11 | 20 | 30 | $1,430 | $72.7K |
| 67028 | 17 | 300 | 400 | $100 | $65.9K |
| J3490 | 94 | 120 | 60 | $470 | $50.8K |
| 92014 | 392 | 2,220 | 160 | $100 | $29.3K |
| 67042 | 21 | 40 | 20 | $1,030 | $22.7K |
| 99214 | 4,988 | 30,450 | 90 | $100 | $19K |
Showing 1–10 of 22
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
3 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 570 | $290 | $166.4K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 830 | $30 | $24.2K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 1,040 | $10 | $7.3K |
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
3 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 35 | 100 | 280 | $650 | $369.9K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 89 | 260 | 420 | $70 | $65.6K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 225 | 730 | 370 | $20 | $30K |
Other providers in the same ZIP code as Tahsin Choudhury, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Laboratory Alliance Of Central New York, LLC | NY | Clinical Medical Laboratory | $2.6M | $10.6M |
| Syracuse Asc, LLC | NY | Ambulatory Surgical Clinic/Center | $5M | $1.8M |
| Digestive Disease Center Of Central New York, LLC | NY | Ambulatory Surgical Clinic/Center | $706K | $3.6M |
| Robert Dracker | NY | Pediatrics Physician | $1.1M | $56.8K |
| Joseph Housel | NY | Dermatology Physician | $1.1M | $0 |
| Richard Stankus | NY | Allergy & Immunology Physician | $58.2K | $347K |
| Sherwin Pollock | NY | Diagnostic Radiology Physician | $349.2K | $30.3K |
| Leslie Woodcock | NY | Ophthalmology Physician | $292.4K | $0 |
| Nedim Ruhotina | NY | Urology Physician | $237K | $850 |
| Gary Leavitt | NY | Diagnostic Radiology Physician | $209.5K | $790 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.